When Oversight Fails: Iowa's $22 Million Contract Pharmacy Scandal and the Structural Fragility of ADAP Financing
On March 6, 2026, the Iowa Department of Health and Human Services filed a nine-page complaint in Polk County District Court alleging that NuCara Specialty Pharmacy failed to remit more than $22 million in 340B program income generated through the state's AIDS Drug Assistance Program (ADAP). According to the filing, NuCara missed eight months of required monthly payments between October 2024 and January 2026, then used those funds to pay unrelated creditors. Iowa terminated the contract the same day it sued. Three days later, on March 9, the state implemented an ADAP waiting list of 1,106 people, the first such waitlist reported to NASTAD in more than a decade.
The Iowa story differs in important ways from Florida's earlier ADAP crisis. Florida's eligibility cuts and formulary restrictions were political choices made under questionable budget claims and without stakeholder engagement. Iowa's failure is structural: a single contract pharmacy relationship spanning 28 years, an oversight architecture incapable of detecting eight months of missed payments in real time, and a federal financing model that has quietly become majority-dependent on rebate revenue states cannot reliably audit. Both crises produce the same outcome for people living with HIV, but they require different policy responses, and conflating them obscures the specific reforms Iowa now demands.
How the Money Was Supposed to Work
The mechanics matter, because they explain the scope of the loss. Under Iowa's contract with NuCara, the pharmacy ordered medications on behalf of the state at the 340B discounted ceiling price. When clients had third-party insurance, NuCara billed insurers at the standard, non-discounted rate, generating "program income" from the spread. NuCara was permitted to retain a $75 dispensing fee per claim and was required to remit the remaining program income to Iowa HHS each month for reinvestment in the program. The lawsuit alleges that NuCara instead "improperly used those 340B savings to pay other creditors" and "no longer has the capital necessary to pay Iowa HHS the program income required under the Contract." A pending acquisition by OneroRX offers no relief; according to the state, OneroRX does not intend to assume NuCara's liabilities.
Iowa's structural exposure to this kind of failure was unusually concentrated. According to NASTAD's 2025 RWHAP Part B ADAP Monitoring Project Annual Report, Iowa's total FY2023 ADAP budget was $12,996,461, with the federal ADAP Earmark contributing just $1,917,626. ADAP rebates allocated to the broader Part B program reached $12,070,445 in FY2023, up from $7,098,397 in FY2022, a 70% year-over-year increase in rebate dependency. Iowa's recorded state general revenue contribution to ADAP was $0. When NuCara stopped remitting program income, Iowa's ADAP had no state-funded redundancy to absorb the loss. The $22 million now in dispute exceeds Iowa's entire FY2023 ADAP budget.
This concentration is not Iowa's alone. Drug rebates generated through 340B now constitute 52% of total ADAP budgets nationally, with the federal ADAP earmark covering only 29%. Federal ADAP appropriations have remained flat in nominal dollars since FY2014, meaning purchasing power has declined 31% since 2005. The rebate-and-program-income revenue stream has quietly become load-bearing infrastructure for HIV treatment access in this country, and Iowa just demonstrated what happens when that infrastructure has a single point of failure.
The Oversight Vacuum
The federal architecture was not designed to detect this kind of contract pharmacy failure quickly, and Government Accountability Office (GAO) testimony delivered to the Senate HELP Committee in October 2025 had already laid out why. Director Michelle Rosenberg's statement documented that HRSA has implemented only five of 20 GAO recommendations to improve 340B oversight, with 15 remaining unaddressed. The agency does not require covered entities to register contract pharmacies for each individual site, leaving HRSA without complete data on contract pharmacy arrangements nationally. HRSA's guidance to covered entities "lacks specificity as it relates to the scope and frequency" of contract pharmacy oversight, and GAO found that some covered entities "performed minimal contract pharmacy oversight" as a result.
The audit footprint is also vanishingly small relative to program scale. HRSA conducts roughly 200 audits of covered entities per year against a covered entity site footprint that grew from about 20,000 in 2013 to more than 55,000 by 2023. HRSA has told Congress repeatedly, across more than a decade of budget requests, that it lacks the regulatory authority to enforce many of the recommendations GAO has flagged. Iowa was operating within a federal oversight system that GAO itself has documented as insufficient. The eight-month detection lag was not surprising. It was predictable.
A Legislator, a Bill, and a Conflict of Interest
The Iowa case carries a political dimension worth naming directly. Iowa Rep. Brett Barker (R) has served as NuCara's vice president of operations since 2012. He also served on the Iowa Board of Pharmacy from May 2017 to December 2021. In January 2026, weeks before the lawsuit was filed, Barker introduced legislation that would prohibit drug manufacturers from restricting the delivery of 340B discounted drugs to contract pharmacies, a policy change that would directly benefit contract pharmacy financial interests including NuCara's. Barker has stated he had no operational knowledge of the matters in the lawsuit and that they involved "departments and actions entirely separate from my work."
Whether Barker had operational knowledge is a question for the litigation. The structural concern for advocates and policymakers is broader and material regardless of how the case resolves: contract pharmacy interests have direct legislative representation in Iowa, the patient-facing safeguards on 340B revenue do not, and the state has no disclosure framework that surfaces this kind of conflict before legislation moves. This pattern is replicated in many statehouses, and it shapes which 340B reforms gain traction and which stall.
Why This Matters Beyond Iowa
The April 2026 ADAP Watch places the Iowa scandal within a system already under enormous and mounting pressure. Nineteen ADAPs report a budget deficit for the current Ryan White HIV/AIDS Program (RWHAP) Part B fiscal year ending March 31, 2027, with Iowa among the nine reporting significant deficits of 5% or greater. Two ADAPs now have active waiting lists (Iowa at 1,106 and Utah at 10), two operate under maximum client caps, and KFF analysis published March 2 documents that 18 states have already adopted cost-cutting changes to ADAPs with five more considering them. The top reported drivers of these deficits include rising per-client drug costs, increasing premium costs, expiration of enhanced premium tax credits, increased client enrollment, and decreased 340B rebate revenue.
The demand pressure is also accelerating. The post-COVID Medicaid unwinding pushed a 30% increase in new ADAP enrollments and an 11% increase in total enrollment compared to 2022. H.R. 1, signed July 4, 2025, is projected to drive an additional surge as more than 10.3 million people lose Medicaid. Iowa's experience is the warning shot. As demand surges and rebate revenue compresses simultaneously, more states are one operational failure away from a waitlist of their own.
What Reform Should Look Like
The temptation in moments like this is to treat the Iowa scandal as a contracting failure, fix the contract, and move on. That response misses the systemic risk the case exposes. Reform needs to address the federal oversight architecture, the state-level operational gaps, and the conflict-of-interest framework that lets contract pharmacy financial interests shape 340B legislation without disclosure. We should be specific about what each level of government should do.
At the federal level, Congress should grant HRSA explicit rulemaking authority over the 340B program. The agency has requested this authority for more than a decade, and the absence of it is the proximate reason 15 of 20 GAO recommendations remain unimplemented. Rulemaking authority should include the power to require site-level contract pharmacy registration, mandatory program income reporting from contract pharmacies serving covered entities, and enforceable corrective action plans following audits. Congress should also increase the federal ADAP earmark to reflect documented enrollment growth and reduce the structural overdependence on rebate revenue that now constitutes 52% of total ADAP budgets. A safety net program majority-funded by a revenue source no federal agency reliably tracks is a safety net engineered for this kind of failure.
At the state level, ADAPs should require monthly attestation and independent audit of contract pharmacy program income remittance. An eight-month detection lag is unacceptable when the funds at stake support life-sustaining medication for people living with HIV. State health departments should also reassess single-vendor dependencies. Iowa's 28-year relationship with NuCara is not unusual in ADAP procurement practice, but the Iowa case demonstrates that contract longevity is not a substitute for ongoing operational scrutiny. Where feasible, ADAPs should diversify contract pharmacy arrangements to eliminate single points of failure, and HRSA's HIV/AIDS Bureau should issue updated guidance encouraging this practice.
State legislatures should adopt conflict-of-interest disclosure requirements for legislators with operational or executive roles at 340B covered entities, contract pharmacies, or third-party administrators. The Iowa case illustrates why this matters. Contract pharmacy interests routinely shape state-level 340B legislation, and patients have no comparable seat at the table. Disclosure does not resolve the underlying tension, but it surfaces it for voters, advocates, and other legislators in time to inform debate.
Patient advocates should also continue pressing for a clear federal definition of "patient benefit" tied to reporting requirements, as CANN's 340B Policy Director has argued in prior analysis. The 340B program was designed to stretch federal resources to reach more eligible patients, not to function as an opaque revenue stream for intermediaries. The recently introduced ACCESS Act and the SUSTAIN 340B discussion draft offer frameworks worth pressure-testing in Congress, and the Iowa case provides a concrete example of why federal standards cannot wait.
The Patient Stake
The 1,106 Iowans now on an ADAP waiting list did not create this failure. They did not negotiate a 28-year single-vendor contract, did not write the federal statute that left HRSA without enforcement authority, and did not introduce legislation that would expand the financial interests of the company that allegedly mishandled their program income. They are simply trying to access HIV treatment, and the architecture built to support that access has now demonstrated a failure mode that other states are structurally exposed to.
The Ending the HIV Epidemic initiative depends on sustained viral suppression, which depends on consistent treatment access, which depends on programs like Iowa's remaining solvent and operationally sound. The reforms outlined here are not abstract. They are the conditions under which a national strategy launched in 2019 can actually succeed. We have the data, we have the GAO recommendations, and we now have a $22 million case study showing what happens when those recommendations sit on a shelf. What we need is the political will to act before more patients find themselves without medication and sitting on a waiting list, praying for someone to do the right thing.
CBO Data Proves Hospital Systems Exploit 340B Drug Program for Billions
The Congressional Budget Office has delivered a damning federal validation of what CANN and other patient advocates have been arguing for years: the 340B Drug Pricing Program has become a $44 billion hospital exploitation scheme. The September 9 report confirms that large health systems are systematically gaming the program to capture massive profits while reducing charity care and consolidating away from the vulnerable communities they claim to serve.
The CBO's findings demolish the hospital industry's primary defense of 340B expansion: that growth reflects rising drug costs rather than system manipulation. The program expanded 565% from $6.6 billion in 2010 to $43.9 billion in 2021, with federal economists confirming that two-thirds of this growth stems from covered entity and third-party behaviors, not pharmaceutical price inflation. As CANN CEO Jen Laws noted, "It is a HELL of a thing that CBO found program growth is driven more by how hospitals and middlemen game the system than by the 'rising drug costs' hospitals always blame."
The implications extend far beyond 340B reform to fundamental questions about healthcare market structure and the accountability of tax-exempt institutions capturing billions in public benefits as “profit” while abandoning charity care and drowning patients in medical debt in the process.
How Hospitals Weaponize 340B for Anti-Competitive Consolidation
The CBO analysis reveals the precise mechanisms through which hospitals transform 340B discounts into acquisition capital. Hospital outpatient departments and satellite clinics control 87% of total 340B spending, providing massive cash flows that traditional community providers cannot match when competing for physician practices or specialty services.
Cancer drugs represent 41% of all 340B spending at approximately $18 billion annually, creating particularly lucrative acquisition targets. When hospitals acquire independent oncology practices, they can immediately capture 340B discounts on existing patient treatments while expanding their geographic footprint. This explains why 70.1% of buyer hospitals in mergers and acquisitions from 2016-2024 were 340B covered entities, compared to just 59.9% of hospitals nationally.
The regulatory framework enables this exploitation through geographic eligibility rules that allow hospitals to extend 340B benefits to satellite facilities serving affluent populations, provided they maintain connection to a qualifying parent institution. Off-site outpatient clinics participating in 340B exploded from 6,100 in 2013 to 27,700 by 2021, with many located in wealthy suburbs far from the low-income communities that justify program participation.
Contract pharmacy arrangements provide additional consolidation leverage, growing 2,400% from approximately 1,000 locations in 2010 to 32,069 by 2025. Hospitals negotiate exclusive arrangements with pharmacy chains, effectively controlling medication access across entire markets while extracting profits from every prescription filled by their "340B-eligible" patients, regardless of the patient's income or insurance status.
Laws captured the patient harm precisely: "hospital systems are exploiting cancer patients to drive revenue that would otherwise be considered 'profit' and further anti-competitive behaviors to the detriment of patient access." The mechanism creates a feedback loop where 340B profits fund acquisitions that eliminate competition, enabling hospitals to raise prices and reduce services while maintaining program eligibility despite providing declining levels of actual charity care.
The Charity Care Shell Game Exposes Regulatory Failure
Hospital claims about using 340B savings to support vulnerable populations collapse under scrutiny of actual charity care data. The Government Accountability Office's 2018 report documented that 340B hospitals experienced "steady decline in both charity care and uncompensated care" during the period of explosive program growth, revealing a fundamental disconnect between rhetoric and practice.
The regulatory structure enables this deception through definitional ambiguity. Hospitals routinely conflate charity care, which involves writing off debt with no patient obligation, with uncompensated care, which includes bad debt that hospitals aggressively collect through lawsuits and wage garnishments. As CANN has emphasized, "charity care is care provided at no cost or debt to the patient. Moving forward, we must not confuse, conflate, or combine generalized uncompensated care with charity care."
Johns Hopkins Hospital demonstrates how prestigious 340B institutions exploit this definitional confusion. The hospital filed more than 2,400 lawsuits against patients since 2009, with cases increasing from 20 in 2009 to 535 in 2016. Despite obtaining wage garnishments in more than 400 cases for a median amount of only $1,438, Johns Hopkins simultaneously received $36 million more in state charity care support than it actually provided.
This pattern reflects systematic regulatory failure rather than isolated incidents. A 2018 GAO survey found that 57% of 340B hospitals do not provide discounted drug prices to low-income, uninsured people at their contract pharmacies. The Health Resources and Services Administration (HRSA) lacks enforcement mechanisms to ensure program benefits reach intended populations, creating an accountability vacuum that hospitals exploit with impunity.
The policy implications prove profound. Medical debt grew from $81 billion in 2016 to $140 billion in 2019 during massive 340B expansion, precisely when enhanced hospital resources should have reduced financial barriers to care. A Pioneer Institute study found Massachusetts General Hospital's charity care dropped from 3.8% to 1% of patient revenue between 2013 and 2020, even as 340B profits increased substantially.
State Legislation Creates Compliance Theater That Benefits Hospitals
The proliferation of conflicting state 340B laws represents a masterclass in regulatory capture. Seven states enacted contract pharmacy protection laws in 2025 alone, joining eight states with similar 2024 legislation. These laws create administrative complexity that large hospital systems navigate easily while imposing crushing compliance burdens on community health centers and rural clinics.
The policy design reveals sophisticated lobbying influence. Hospital-backed legislation focuses on procedural requirements and reporting obligations that sound patient-protective but actually entrench existing power structures. Meanwhile, substantive reforms addressing charity care requirements, geographic restrictions, or patient benefit mandates remain absent from most state proposals.
One rural federally qualified health center reported 60% erosion in 340B savings resulting in a loss of $531,720 per year, forcing closure of oral health centers serving low-income patients. Large hospital systems with dedicated compliance departments experience no similar hardships, instead benefiting from reduced competition as smaller providers struggle with regulatory complexity.
Federal courts have begun recognizing this manipulation. West Virginia's S.B. 325 was blocked in December 2024when Judge Thomas E. Johnston ruled it "stands as an obstacle to achieving the federal objective of preventing fraud in the 340B Program." The emerging circuit split creates additional uncertainty that benefits well-resourced hospitals while harming smaller safety-net providers unable to navigate conflicting legal requirements.
Even supportive officials recognize the limitations. Utah Governor Spencer Cox allowed his state's legislation to become law without signature, explicitly stating the bill "does not go far enough to ensure cost savings experienced by 340B covered entities are passed onto patients." This acknowledgment exposes the fundamental inadequacy of state-level approaches to addressing federal program failures.
ACCESS Act Addresses Root Causes, Not Just Symptoms
The recently reintroduced 340B ACCESS Act represents the first comprehensive federal response to CBO-confirmed abuses. As CANN stated in its press release, "The 340B ACCESS Act is an excellent starting place to reform the 340B program. The legislation, in deep alignment with currently proposed federal rules, puts patients in the driver's seat for the first time since the program was established in 1992."
The legislation addresses structural incentives that enable hospital exploitation through hospital transparency requirements and administrative fee limits that target the accountability vacuum in current regulations. The bill's provisions for "reducing patient out-of-pocket costs through sliding fee scale drug discounts" directly address the patient access barriers created by current hospital practices.
Crucially, the ACCESS Act would "ensure PBMs appropriately reimburse on 340B drugs" and limit "third-party administrator fees," addressing the middleman extraction that enables massive profit-taking from vulnerable patient populations. The legislation also addresses gaps in the Ryan White Program's 318 grants that created the issues highlighted in the Sagebrush lawsuit, where manufacturers challenge STI clinic eligibility for 340B participation.
The legislation is far from perfect, including a six-month limitation on telehealth provisions that may harm people seeking outpatient methadone services and legitimate PrEP clinics. However, as CANN's Kalvin Pugh noted, "The 340B ACCESS Act is a critical start to putting patient need over hospital greed and finally bringing the program back to its original intent”
Federal Action Required to Restore Program Integrity
The CBO report eliminates any remaining doubt about 340B's transformation from safety-net support to hospital profit extraction scheme. The data confirms what patient advocates have documented: hospitals systematically reduce charity care while using 340B revenue to finance anti-competitive consolidation that harms the communities supposedly being served.
State legislative responses have failed because they address symptoms rather than causes. The ACCESS Act offers comprehensive federal reform that could restore program integrity by ensuring 340B savings benefit patients rather than hospital shareholders. Without such intervention, the program will continue enriching hospital systems while people living with HIV lose access to Ryan White clinics, cancer patients face treatment delays due to provider consolidation, and rural communities watch their last remaining healthcare options disappear despite billions in program funding ostensibly flowing to support them.
The choice facing policymakers is clear: prioritize patient need over hospital greed through meaningful federal reform, or continue enabling a system that betrays every principle underlying the 340B program's original mission.